Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study

European Journal of Heart Failure

Volumn 21, Issue 8, 2019, Pages 998-1007

  Wachter, Rolf ^a,w   Senni, Michele ^b,w   Belohlavek, Jan ^c,w   Straburzynska Migaj, Ewa ^d,w   Witte, Klaus K ^e   Kobalava, Zhanna ^f,w   Fonseca, Candida ^g,w   Goncalvesova, Eva ^h,w   Cavusoglu, Yuksel ^i,w   Fernandez, Alberto ^j   Chaaban, Said ^k,w   Bøhmer, Ellen ^l   Pouleur, Anne Catherine ^m,w   Mueller, Christian ⁿ   Tribouilloy, Christophe ^o,w   Lonn, Eva ^p,w   A L Buraiki, Jehad ^q   Gniot, Jacek ^r,w   Mozheiko, Maria ^s,w   Lelonek, Malgorzata ^t,w   Noè, Adele ^u   Schwende, Heike ^u   Bao, Weibin ^u   Butylin, Dmytro ^u   Pascual, Domingo ^w   Dominguez, Antonio Reyes ^w   Horacek, Thomas ^w   del Rio, Enrique Garcia ^w   Mueller, Christian Eugen ^w   Slanina, Miroslav ^w   vom Dahl, Juergen ^w   Ryding, Alisdair ^w   Moriarty, Andrew ^w   Robles, Manuel Beltran ^w   Villota, Julio Nunez ^w   Quintana, Antonio Garcia ^w   Nitschke, Thorsten ^w   Manuel Garcia Pinilla, Jose ^w   Bonet, Luis Almenar ^w   Filali zaatari, MD, Samia ^w   Spinar, Jindrich ^w   Musial, Wlodzimierz ^w   Abdelbaki, Khaled ^w   Fehske, Wolfgang ^w   Bott, Michael Carlos ^w   Hoegalmen, Geir ^w   Leiro, Marisa Crespo ^w   Ozcan, Ismail Turkay ^w   Mullens, Wilfried ^w   Kryza, Radim ^w   Al Ani, Riadh ^w   Loboz Grudzien, Krystyna ^w   Ermoshkina, Lyudmila ^w   Hojerova, Silvia ^w   Fernandez, Alberto Alfredo ^w   Spinarova, Lenka ^w   Lapp, Harald ^w   Bulut, Efraim ^w   Almeida, Filipa ^w   Vishnevsky, Alexander ^w   Belicova, Margita ^w   Witte, Klaus ^w   Wong, Kenneth ^w   Droogne, Walter ^w   Delforge, Marc ^w   Peterka, Martin ^w   Olbrich, Hans Georg ^w   Carugo, Stefano ^w   Nessler, Jadwiga ^w   McGill, Thao Huynh ^w   Huegl, Burkhard ^w   Akin, Ibrahim ^w   Moreira, Ilidio ^w   Baglikov, Andrey ^w   Thambyrajah, Jeetendra ^w   Hayes, Chris ^w   Barrionuevo, Marcelo Raul ^w   Yigit, Zerrin ^w   Kaya, Hakki ^w   Klimsa, Zdenek ^w   Radvan, Martin ^w   Kadel, Christoph ^w   Landmesser, Ulf ^w   Di Tano, Giuseppe ^w   Lisik, Malgorzata Buksinska ^w   Oliveira, Luis ^w   Marques, Irene ^w   Santos, Luis Miguel ^w   Lenner, Egon ^w   Letavay, Peter ^w   Bueno, Manuel Gomez ^w   Mota, Paula ^w   Wong, Aaron ^w   Bailey, Kristian ^w   Foley, Paul ^w   Hasbani, Eduardo ^w   Virani, Sean ^w   Massih, Tony Abdel ^w   Al Saif, Shukri ^w   Taborsky, Milos ^w   Kaislerova, Marta ^w   Motovska, Zuzana ^w   Praha, ^w   Cohen, Aron Ariel ^w   Logeart, Damien ^w   Endemann, Dierk ^w   Ferreira, Daniel ^w   Brito, Dulce ^w   Kycina, Peter ^w   Bollano, Entela ^w   Basilio, Enrique Galve ^w   Rubio, Lorenzo Facila ^w   Aguado, Marcos Garcia ^w   Schiavi, Lilia Beatriz ^w   Zivano, Daniel Francisco ^w   Sayed, Ali El ^w   Heyse, Alex ^w   Schee, Alexandr ^w   Polasek, Rostislav ^w   Houra, Marek ^w   Seronde, Marie France ^w   Galinier, Michel ^w   Noutsias, Michel ^w   Schwimmbeck, Peter ^w   Voigt, Ingo ^w   Westermann, Dirk ^w   Pulignano, Giovanni ^w   Vegsundvaag, Johnny ^w   Alexandre Da Silva Antunes, Jose ^w   Monteiro, Pedro ^w   Stevlik, Jan ^w   Hulkoova, Beata ^w   Juan Castro Fernandez, Antonio ^w   Davies, Ceri ^w   Squire, Iain ^w   Meyer, Philippe ^w   Sheppard, Richard ^w   Sahin, Tayfun ^w   Sochor, Karel ^w   De Geeter, Guillaume ^w   Schmeisser, Alexander ^w   Weil, Joachim ^w   Soares, Ana Oliveira ^w   Bulashova, Olga Vasilevna ^w   Oshurkov, Andrey ^w   Sunderland, Shahid Junejo ^w   Glover, Jason ^w   Exequiel, Tomas ^w   Decoulx, Eric ^w   Meyer, Sven ^w   Muenzel, Thomas ^w   Frioes, Fernando ^w   Arbolishvili, Georgy ^w   Tokarcikova, Anna ^w   Karlstrom, Patric ^w   Carles Trullas Vila, Joan ^w   Perez, Gonzalo Pena ^w   Sankaranarayanan, Rajiv ^w   Nageh, Thuraia ^w   Alasia, Diego Cristian ^w   Refaat, Marwan ^w   Demirkan, Burcu ^w   Al Buraiki, Jehad ^w   Karabsheh, Shadi ^w   more..

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^g NOVA MEDICAL SCHOOL   (Portugal)

^h Odd Srdcovehozlyhavania A Transplantacie   (Slovakia)

ⁱ OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^j Sanatorio Modelo de Quilmes   (Argentina)

^k Hammoud Hospital   (Lebanon)

^l INNLANDET HOSPITAL TRUST   (Norway)

^m CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o AMIENS UNIVERSITY HOSPITAL   (France)

^p HAMILTON HEALTH SCIENCES   (Canada)

^q KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^r SP ZOZ Szpital Specjalistyczny   (Poland)

^s Yaroslavl Regional Clinical Hospital of War Veterans   (Russian Federation)

^t MEDICAL UNIVERSITY OF LODZ   (Poland)

^u NOVARTIS PHARMA AG   (Switzerland)

^v HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^w Universidad de Murcia ^*

more..

Author keywords

Acute decompensated heart failure; Angiotensin receptor neprilysin inhibitor; Heart failure; Hospitalisation; Sacubitril valsartan

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART HEMODYNAMICS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; HEART FAILURE; HEMODYNAMICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; NEPRILYSIN; PATIENT DISCHARGE; TETRAZOLES; TREATMENT OUTCOME;

EID: 85067464368     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1498     Document Type: Article

References (24)

1. Christ M, Störk S, Dörr M, Heppner HJ, Müller C, Wachter R, Riemer U, Trend HF Germany Project. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 2016;18:1009–1018.
2. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173–1184.
3. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalisation for heart failure. Nat Rev Cardiol 2015;12:220–229.
4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062–1073.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
6. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54–61.
7. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail 2018;20:963–972.
8. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539–548.
9. Pascual-Figal D, Wachter R, Senni M, Belohlavek J, Noè A, Carr D, Butylin D. Rationale and design of TRANSITION: a randomised trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail 2018;5:327–336.
10. World Medical Association. WMA declaration of Helsinki - Ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (11 March 2019).
11. Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gómez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomised comparison of two uptitration regimens. Eur J Heart Fail 2016;18:1193–1202.
12. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534–1541.
13. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomised trial. JAMA 2013;309:1125–1135.
14. DeVore A. PIONEER-HF: results of the open-label extension. Science News from ACC 2019. https://professional.heart.org/professional/EducationMeetings/EducationMeetings/UCM_503744_Science-News-from-ACC-2019.jsp (9 April 2019).
15. Kristensen SL, Martinez F, Jhund PS, Arango JL, Bělohlávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J 2016;37:3167–3174.
16. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams F, Hernansez AF, Fonarow GC. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351–366.
17. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, Klebs S, Wirta SB, Kostev K. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail 2019;21:588–597.
18. Desai AS. The three-phase terrain of heart failure readmissions. Circ Heart Fail 2012;5:398–400.
19. Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, Lee DS. Lifetime analysis of hospitalisations and survival of patients newly admitted with heart failure. Circ Heart Fail 2012;5:414–421.
20. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Dosing of beta-blocker therapy before, during, and after hospitalisation for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol 2008;102:1524–1529.
21. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38:1883–1890.
22. Senni M, McMurray JJ, Wachter R, McIntyre HF, Anand IS, Duino V, Sarkar A, Shi V, Charney A. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail 2018;20:491–500.
23. Andries G, Yandrapalli S, Aronow WS. Benefit-risk review of different drug classes used in chronic heart failure. Expert Opin Drug Saf 2019;18:37–49.
24. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.